In our cohort, TMB showed an inverse correlation with immune score in IDH-wildtype samples (R = −0.46, p = 0.03) (Figure 2C), and no correlation in IDH-mutant gliomas (Figure 2D), suggesting that the IDH mutation has an impact on the correlation of TMB and immune score. This evidence concerns the gene IDH1 and central nervous system cancer.